Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Mersana Therapeutics Inc
MRSNCurrent price
0.31 USD
-0.051 USD (-13.98%)
Last closed
0.38 USD
Company
www.mersana.com
ISIN
US59045L1061
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
49 565 752 USD
Yield for 12 month
-87.81 %
1Y
3Y
5Y
10Y
15Y
MRSN
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Address: 840 Memorial Drive, Cambridge, MA, United States, 02139
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4.71 USDP/E ratio
–Dividend Yield
–Current Year
+40 497 000 USD
Last Year
+36 855 000 USD
Current Quarter
+16 361 000 USD
Last Quarter
+12 598 000 USD
Current Year
+38 869 000 USD
Last Year
-111 414 000 USD
Current Quarter
+15 961 000 USD
Last Quarter
+12 598 000 USD
Key Figures MRSN
1 year
3 years
5 years
10 years
EBITDA
-71 708 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-24.73 %
PEG Ratio
–
Return On Equity TTM
-505.14 %
Wall Street Target Price
4.71 USD
Revenue TTM
40 497 000 USD
Book Value
-0.082 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
52.90 %
Dividend Yield
–
Gross Profit TTM
-32 523 000 USD
Earnings per share
-0.56 USD
Diluted Eps TTM
-0.56 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-170.86 %
Dividend Analytics MRSN
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History MRSN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation MRSN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
4.66
Price Sales TTM
1.22
Enterprise Value EBITDA
-2.20
Price Book MRQ
32.03
Financials MRSN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators MRSN
For 52 weeks
0.26 USD
2.88 USD
50 Day MA
0.42 USD
Shares Short Prior Month
9 678 480
200 Day MA
1.34 USD
Short Ratio
3.24
Shares Short
10 060 810
Short Percent
8.81 %
BeatStart